Crowdonomics
All companies
Curenta logo

Curenta

Operating

Curenta Enterprise Corp.

Healthcare · Technology · Laguna Hills, DE · Founded 2020

Reimaging the long-term pharmacy

Post-money valuation ⓘ
$28.9M
As of Apr 2022 · from Reg CF Offering (2022) · pre-money + amount raised, not a traded price
Total raised
$1,531,797
Crowd $99K · Private $1.4M · 2 rounds since 2022
Latest share price
$16.00
Reg CF · Common Stock · Jan 2022 offering price

Financials

FY2019–FY2020 · from SEC filings · hover any figure for its source
$0
−$800
2019
$18K
−$239K
2020
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019 reviewed
FY2020 reviewed
Income statement
Revenue
$0
$17,521
Cost of goods sold
$0
$13,455
Gross margin
—
23%
Net income
-$800
-$239,201
Taxes paid
$800
$800
Balance sheet
Cash
$0
$33,691
Accounts receivable
$0
$8,030
Total assets
$0
$90,912
Short-term debt
$0
$77,554
Long-term debt
$0
$2,400
Total liabilities
$0
$79,954
Other
Headcount
—
44

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$28.8M
pre-money
Reg CF · Common · Jan 2022

Blue bars are the pre-money valuation the company stated for a priced round.

Fundraising history

Raised $98.8K / $1.1MInvestors 91Post-money $28.9M
Raised $1.4MInvestors 14

Team

7 people
Ramy Barsoum MikhailFounder
Chief Executive Officer

Licensed Pharmacist / MBA Maastricht School of Management A CA licensed pharmacist and MBA degree holder from MsM with 15+ years of experience in retail and Long-Term Care pharmacies & 5 years leading a 12 pharmacies-consortium focusing on long-term care, serving 15,000 beds.

Ghada ElWahsh
Head of Product

Built one of the first online pharmacies in the MENA region. A product enthusiast with 7 years journey in health tech product management. Leading product in Curenta for the supply and demand sides.

Ryan Soo Hoo
Director of Business Development

PharmD / University of Health Sciences and Pharmacy in St. Louis A CA licensed PharmD and published clinical oncology researcher with pharmacy enterprise sales experience, focused on novel oncology drug-delivery systems. Utilizing his insight and experience in inpatient and outpatient pharmacy, Ryan is leading the team in building foundational business strategies with Long-Term Care facilities and Treatment Centers.

Amir Barsoum Mikhail
Chairman

Amir Barsoum is the Founder and CEO of Vezeeta, a leading digital healthcare platform that offers patients a personalized, end-to-end healthcare experience from diagnosis to delivery of ongoing care and medications. Recognized as one of Fortune’s 40 under 40 global healthcare leaders in 2020, Amir helped pave the path for Vezeeta to become one of the fastest-growing health tech start-ups in the Middle East and Africa region and guided the expansion within the B2B landscape, with a growing footprint in North America, and Southeast Asia. Barsoum has helped shape the greater business community as an active angel investor and mentor for start-ups around the globe. He currently sits on the Board of three digital healthcare start-ups in the US, that focus on long-term care, revenue cycle management, and AI diagnostics. He is also a member of the Board of directors of Endeavor Egypt, and Entrepreneurs' Org, and offers guidance and consultations to major international institutions such as Bloomberg Health Council, Forbes Business Council, Endeavor, and MIT Legatum Centre. Prior to founding Vezeeta, he served as a Managing Consultant at McKinsey & Co. across Europe, and the Middle East region, and also held the position of Head of Strategic Planning at AstraZeneca. A pharmacist by education, Barsoum holds an MBA from MIT Sloan School of Management.

Armstrong Chu
Pharmacist In Charge (PIC)

PharmD / Notre Dame of Maryland University A CA licensed PharmD with 5 years long-term care pharmacy experience. Armstrong is leading the pharmacy team in the daily interactions with the Long-Term Care facilities.

Mario Karras
Board Observer

Mario specializes in M&A and international tax planning. During his time at Loyola Law School, Los Angeles, Mario was a member of the International Law Review and the Honors Tax Policy Colloquium. He also holds a B.B.A. from Emory University's Goizueta Business School in Finance, Strategy Management, and Entrepreneurship.

Nancy Yani
Operations Manager

A CA licensed pharmacist with 5 years experience in pharmacies operations management. Nancy used to run a group of retail and long-term care pharmacies, serving 2,000 beds.

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Delinquent

Filed 0 of 5 annual reports (FY2021–FY2025)

Missing: 2021, 2022, 2023, 2024, 2025

91 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-USep 29, 20220001665160-22-002534
    EDGAR
  • Form C-UMay 2, 20220001665160-22-001465
    EDGAR
  • Form CJan 31, 20220001665160-22-000177
    EDGAR
  • Form DJan 13, 20220001899432-22-000001
    EDGAR
Source: ManualCIK 0001899432DEShare price $16.00

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.